References

1-     Vinson BR, Holtmann G. Onset of action and efficiency of STW 5 in the clinical setting in patients with Functional Dyspepsia and Irritable Bowel Syndrome. Gastroenterology 2013; 144: S682 (Mo1881)

2-     Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogasts). Phytomedicine 2006; 13: SV 20-35

3-     Ottillinger B, et al. STW 5 (Iberogast®) – a safe and effective standard in the treatment of functional gastrointestinal disorders. Wien Med Wochenschr 2013; 163: 65-72

4-     Iberogast Package Insert

5-     Hunt R, Quigley E et al. World Gastroenterology Organisation Global Guidelines: Coping with common GI symptoms in the community. http://www.worldgastroenterology.org/UserFiles/file/guidelines/common-gi-symptoms-english-2013.pdf

6-     El-Serag HB, Talley NJ. Systematic review: health related quality of life in functional dyspepsia.

      Aliment Pharmacol Ther 2003; 18: 387-393

7-     Vinson B. Development of Iberogast: clinical evidence for multicomponent herbal mixtures. In: Cooper R, Kronenberg F, editors. Botanical medicine: from bench to bedside. New Rochelle: Mary Ann Liebert 2009; pp. 167-189

8-     Bayer Intranet Link: https://mynetworld.bhc.cnb/wps/myportal/mynetworld/newsroom?nl=/news/cc/2015/6/15/basel_iberogast_20150615.aspx&l=en

9-     Layer P, Andresen V, Pehl C, Allescher H. Irritable Bowel Syndrome: German Consensus Guidelines on Definition, Pathophysiology and Management. German Society of Digestive and Metabolic Diseases (DGVS) and German Society of Neurogastroenterology and Motility (DGNM). Z Gastroenterol 2011; 49: 237-293

10-  Kroll U, Cordes C, Pharmaceutical prerequisites for a multi-target therapy. Phytomedicine 2006; 13: SV 12-19

11-  Schemann M, Michel K, Hohenester B, Ruhl A. Region-specific effects of STW 5 and its components in gastric fundus, corpus and antrum. Phytomedicine 2006; 13: SV 90-99

12-  Melzer J, Rösch W, Reichling J, et al. Metaanalysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20: 1279-1287

13-  Allescher HD. Functional dyspepsia – A multicausal disease and its therapy. Phytomedicine 2006; SV 13: 2-11

14-  Nieber K, Michael S, Grotzinger K, Rauwald JW, Kelber O. Anti-inflammatory effect of STW 5, STW 6 and isolated extracts on the rat small intestine. Z Phytotherapie 2008; 29: S29

15-  Liu CY, Müller MH, Glatzle J, Weiser D, Kelber O, Enck P, Grundy D, Kreis ME. The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004; 16: 759-764

16-  Madisch A, Holtmann G, Plein K, et al. Treatment of irritable bowel syndrome with herbal preparations. Aliment Pharmacol Ther 2004; 19: 271-279

17-  Wagner H. Multitarget therapy - The future of treatment for more than just function dyspepsia. Phytomedicine 2006; 13: SV 122-129

18-  Heinle H, Hagelauer D, Pascht U, Kelber O, Weiser D. Intestinal spasmolytic effects of STW 5 (Iberogast) and its components. Phytomedicine 2006; 13: SV 75-79

19-  Hohenester B, Rühl A, Kelber O, Schemann M. the herbal preparation STW-5 (lberogast®) has

potent and region-specific effects on gastric motility. Neurogastroenterol Motil 2004; 16: 765-773

20-  Kelber O, Gaedcke F, Steinhoff B, Winterhoff H on behalf of the Working Group “Efficacy and Safety” of Kooperation Phytopharmaka, Bonn (Germany). Ethanol in herbal medicinal products in children. Pharm Ind 2008; 70: 1124-1127